Nuclear medicine and Wall Street: an evolving relationship
M Sherman, R Levine - Journal of Nuclear Medicine, 2019 - Soc Nuclear Med
Until recently, it has been challenging to engage Wall Street and large pharmaceutical
companies in radiopharmaceutical opportunities. The modest economic prospects of most …
companies in radiopharmaceutical opportunities. The modest economic prospects of most …
[PDF][PDF] Tackling the last mile: a major component to successfully establish radioligand therapy
KL Pomykala, M Würker… - Journal of Nuclear …, 2023 - Soc Nuclear Med
The term last mile originates from the telecommunication industry and describes the difficulty
of connecting the end customer to the main telecommunication networks (1). Successfully …
of connecting the end customer to the main telecommunication networks (1). Successfully …
Theranostics: leveraging molecular imaging and therapy to impact patient management and secure the future of nuclear medicine
Nuclear medicine is experiencing a renaissance, with US Food and Drug Administration
approval recently being obtained for theranostic agents and a wide variety of such agents …
approval recently being obtained for theranostic agents and a wide variety of such agents …
Mars shot for nuclear medicine, molecular imaging, and molecularly targeted radiopharmaceutical therapy
RL Wahl, P Chareonthaitawee, B Clarke… - Journal of Nuclear …, 2021 - Soc Nuclear Med
The Society of Nuclear Medicine and Molecular Imaging created the Value Initiative in 2017
as a major component of its strategic plan to further demonstrate the value of molecular …
as a major component of its strategic plan to further demonstrate the value of molecular …
Training the next generation of radiopharmaceutical scientists
Training the next generation of radiopharmaceutical scientists - ScienceDirect Skip to main
contentSkip to article Elsevier logo Journals & Books Search RegisterSign in View PDF …
contentSkip to article Elsevier logo Journals & Books Search RegisterSign in View PDF …
[HTML][HTML] Commercial and business aspects of alpha radioligand therapeutics
E Ostuni, MRG Taylor - Frontiers in Medicine, 2023 - frontiersin.org
Radioligand therapy (RLT) is gaining traction as a safe and effective targeted approach for
the treatment of many cancer types, reflected by a substantial and growing commercial …
the treatment of many cancer types, reflected by a substantial and growing commercial …
The cost of bringing a radiopharmaceutical to the patient's bedside
AD Nunn - Journal of Nuclear Medicine, 2007 - Soc Nuclear Med
The approval of new imaging agents has slowed, much as for therapeutic drugs. Schering
and Amersham, for instance, each spent about $150 million a year for the period 1999–2004 …
and Amersham, for instance, each spent about $150 million a year for the period 1999–2004 …
Advancing nuclear medicine through innovation-National Research Council and Institute of Medicine of the National Academies* The National Academies Press …
A Hyatt - Journal of Radiotherapy in Practice, 2009 - cambridge.org
Although this is a report written about the state of Nuclear Medicine in USA the challenges
faced are not unique and the call for combined research involving health care, industry and …
faced are not unique and the call for combined research involving health care, industry and …
Bench-to-bedside theranostics in nuclear medicine
The optimum selection of the appropriate radiolabelled probe for the right target and the
right patient is the foundation of theranostics in personalised medicine. In nuclear medicine …
right patient is the foundation of theranostics in personalised medicine. In nuclear medicine …
Nuclear medicine at a crossroads
HR Schelbert - Journal of Nuclear Medicine, 2011 - Soc Nuclear Med
The growth of molecular imaging heightens the promise of clinical nuclear medicine as a
tool for individualization of patient care and for improvement of health-care outcomes …
tool for individualization of patient care and for improvement of health-care outcomes …